In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Ventures: Recycling R&D Assets

Executive Summary

GSK's Ventures swaps unexploited and non-core R&D assets for equity in promising young companies, giving their programs a second chance in someone else's hands-at no cost.

You may also be interested in...

Brane's Brain R&D Spun Out, Seeks Funding

Nikem spun out its R&D assets with about a years' worth of funds to pursue development of its neuropathic pain and Parkinson's disease compounds, which are currently in preclinical development. The company, Brane, is seeking Series A funding.

Can In-Licensing Models Substitute for Discovery?

Has a new biotech business model emerged for pure drug development companies, which start as corporate shells with top flight management teams and then proceed to in-license and further develop multiple products? While the business model is not new, clearly drug development is more fashionable today than drug discovery within the institutional investor community. The real question is whether the in-licensing model works any better than discovery.

The Passion for Late-Stage Deals (Second of a two-part series)

Late-stage compounds are more expensive than ever; deals are now pushing the boundaries of economic viability. Drug companies are therefore looking for ways to cost-effectively expand their late-stage pipelines and expand their criteria for in-licensing candidates. In order to keep valuable development-stage products moving through its pipeline, rather than stopping some in favor of others it judges to be superior, Lilly has been trying to out-license assets to companies with spare development capacity. Lilly can buy the products back later if they prove worthwhile.Meanwhile, Abbott's late-stage dealmaking, while hardly inexpensive, aims to increase the set of choices, lower the cost, and increase the profitability of in-licensing by focusing on franchise markets.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts